Clinical Trial Update: Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rigosertib plus pembrolizumab in unresectable/metastatic melanoma refractory to PD-1 inhibitors; the study is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Rigosertib (rigosertib)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Status: SUSPENDED